MedTrace Logo

Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19

NCT04498936 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2020-11-12

No results posted yet for this study

Summary

The efficacy of treating COVID-19 infection by using Sofosbuvir/Ledipasvir and Nitazoxanide will be examined. Included patients will be into 3 groups. The 1st group will receive Sofosbuvir/Ledipasvir plus the standard care treatment (SCT). The 2nd group will take Nitazoxanide and SCT, while the 3rd group will receive only SCT. Then the clinical improvement and the rate of PCR change from positive to negative will be evaluated in each group.

Conditions

Interventions

DRUG

Sofosbuvir and Ledipasvir

Evaluate the efficacy of Sofosbuvir/Ledipasvir in treatment of COVID-19

DRUG

Nitazoxanide

Evaluate the efficacy of Nitazoxanide in treatment of COVID-19

Sponsors & Collaborators

  • Helwan University

    collaborator OTHER

  • Assiut University

    lead OTHER

Principal Investigators

  • Mohammed A Medhat, PhD · Assiut University

  • Mohamed El Kassas, PhD · Helwan University

  • Haidi K Ramadan, PhD · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-15
Primary Completion
2020-10-30
Completion
2020-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04498936 on ClinicalTrials.gov